Did you know that type 1 diabetes is the most common metabolic disease in children and adolescents?

We conduct studies in Belgium, Germany, the UK, Poland, and Sweden for the early detection of an increased genetic risk of type 1 diabetes and prevention of disease development.

 

 

Increased risk of type 1 diabetes: Early detection – preventive treatment

Freder1k: early detection for infants (up to four months)
in Bavaria, Lower Saxony, Saxony and Thuringia

 

 

 

Prevention study for infants with an increased risk for type 1 diabetes

POInT: for infants at an increased genetic
risk between four and seven months old

 

 

 

WE RESEARCH. WE DEVELOP. WE FIGHT.

FOR A WORLD WITHOUT TYPE 1 DIABETES.

 

© Helmholtz Zentrum München / Jörg Simanowski (Markenfotografie)

The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was launched in 2015 and brings together several academic research institutions and hospitals in Europe. GPPAD aims to establish an international infrastructure for studies dedicated to preventing the development of type 1 diabetes.

 

 

More than

As part of the Freder1k study, we have already assessed the risk of type 1 diabetes in more than 225,000 infants

More than 

children are taking part in our POInT prevention study

 

GPPAD locations in five countries are making every effort to achieve a world without type 1 diabetes